Delivery Order SPE2DR25D2213-SPE2DR26F6DBE
Award Date 12/12/25
Potential Completion Date 12/15/25
Potential Value $2K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $2,447.64 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 1, 2025, with completion scheduled for December 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults 18 years and older, and...
- The U.S. Defense Logistics Agency awarded a delivery order valued at $14,637.70 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price delivery order was issued without a set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention...
- The Defense Logistics Agency awarded a delivery order valued at $1,263.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price delivery order represents a non-competitive set-aside award and is being performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B virus infection in adults 18...
- The Defense Logistics Agency awarded a delivery order valued at $8,158.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 1, 2025, with an ultimate completion date of December 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor's corporate office located in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine used for adult immunization, representing part of the...
- The Defense Logistics Agency awarded a delivery order valued at $8,424.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 2, 2025, with completion expected by September 3, 2025. This delivery order represents a firm fixed-price contract with no set-aside designation, awarded through competitive procurement. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for...
- The Defense Logistics Agency awarded a delivery order valued at $105,310.00 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 23, 2025, with completion targeted for July 24, 2025. This firm fixed price delivery order was awarded without set-aside designation through competitive procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 11, 2025, with completion expected by September 12, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and will be performed at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults 18 years of age and older,...
- The Defense Logistics Agency awarded a delivery order valued at $1,263.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with a completion date of June 2, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order was placed to support federal medical procurement needs, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for...
- The Defense Logistics Agency awarded a delivery order valued at $127,248.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 12, 2025, with an ultimate completion date of August 13, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization in adults. This delivery order is a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,605.90 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with ultimate completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults 18 years of age and...